Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Golden Cariboo (CSE:GCC) (OTC:GCCFF) Expands Gold Footprint in BC (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Evolus Inc EOLS

Healthcare Drug Manufacturers - Specialty & Generic
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.


NDAQ:EOLS - Post by User

Evolus Inc
Bullboard Posts
Next >>
User Avatar Image
(4)
•••
  • AviseAnalyticsX
Post by AviseAnalyticson Aug 04, 2023 8:30am
172 Views
Post# 35572816

EVOLUS: NEXT BIG THING IN THE PERFORMANCE BEAUTY INDUSTRY

EVOLUS: NEXT BIG THING IN THE PERFORMANCE BEAUTY INDUSTRY
$EOLS

Excited to share an article about Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products. The Company's product Jeuveau has been the fastest-growing neurotoxin in the U.S. for two consecutive years.

Evolus will expand its product portfolio to include a line of five different fillers beginning in 2025. The Company will likely achieve net revenues of $700 million by 2028, representing a 29% CAGR. This rapidly expanding Company serves a highly under-penetrated market and hence seems poised for exponential growth.
 
Read on to know more:
https://www.aviseanalytics.com/evolus-next-big-thing-in-the-performance-beauty-industry/

Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities